FindTrial
Sign In

Evaluation of heart disease risk in type 2 Diabetes Mellitus patients using FRS, Q-RISK3, INTERHEART Risk Scores & their correlation with lipoprotein (a) level.

Evaluation of cardiovascular disease risk in type 2 diabetes mellitus patients using framingham risk score, qrisk3, interheart risk scores and their correlation with lipoprotein (a) level.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/08/044536
Enrollment
89
Registered
2022-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Dr Ramesh Kumar Chandak
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: With or Without Microvascular Complications of type 2 DM

Exclusion criteria

Exclusion criteria: 1 Previous history of CVD. 2 Patients with macrovascular complications of diabetes. 3 Terminally ill. 4 Severe liver and renal insufficiency. 5 Type 1 DM 6 Cancer. 7 Thyroid dysfunctions. 8 Severe mental illness. 9 Pregnancy. 10 Peripheral artery disease. 11 Hemolytic disease. 12 Fever & goiter. 13 Sleep apnea syndrome. 14 Severe disabilities.

Design outcomes

Primary

MeasureTime frame
To assess CVD risk in patients of type 2 Diabetes mellitus using various risk scores- FRS,Q RISK 3 ,and Interheart risk score.Timepoint: 6 months—

Secondary

MeasureTime frame
to assess lipoprotein a and compare anthropometric parameters in type 2 DM patientsTimepoint: 3 months—

Countries

India

Contacts

Public ContactDr Sonali Sharma

RUHS-CMS

sonalisharma14@gmail.com9414314678

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026